Research Priorities for Precision Medicine in NAFLD

Paula Iruzubieta; Ramon Bataller; María Teresa Arias-Loste; Marco Arrese; José Luis Calleja; Graciela Castro-Narro; Kenneth Cusi; John F. Dillon; María Luz Martínez-Chantar; Miguel Mateo; Antonio Pérez; Mary E. Rinella; Manuel Romero-Gómez; Jörn M. Schattenberg; Shira Zelber-Sagi; Javier Crespo; Jeffrey V. Lazarus

doi:10.1016/j.cld.2023.01.016

Research Priorities for Precision Medicine in NAFLD

Paula Iruzubieta, Ramon Bataller, María Teresa Arias-Loste, Marco Arrese, José Luis Calleja, Graciela Castro-Narro, Kenneth Cusi, John F. Dillon, María Luz Martínez-Chantar, Miguel Mateo, Antonio Pérez, Mary E. Rinella, Manuel Romero-Gómez, Jörn M. Schattenberg, Shira Zelber-Sagi, Javier Crespo, Jeffrey V. Lazarus

School of Public Health

University of Haifa

Research output: Contribution to journal › Review article › peer-review

Abstract

NAFLD is a multisystem condition and the leading cause of chronic liver disease globally. There are no approved NAFLD-specific dugs. To advance in the prevention and treatment of NAFLD, there is a clear need to better understand the pathophysiology and genetic and environmental risk factors, identify subphenotypes, and develop personalized and precision medicine. In this review, we discuss the main NAFLD research priorities, with a particular focus on socioeconomic factors, interindividual variations, limitations of current NAFLD clinical trials, multidisciplinary models of care, and novel approaches in the management of patients with NAFLD.

Original language	American English
Pages (from-to)	535-551
Number of pages	17
Journal	Clinics in Liver Disease
Volume	27
Issue number	2
DOIs	https://doi.org/10.1016/j.cld.2023.01.016
State	Published - May 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Disease phenotyping
Multidisciplinary care
NAFLD
Non-invasvie tests (NITs)
Precision medicine

All Science Journal Classification (ASJC) codes

Hepatology

Access to Document

10.1016/j.cld.2023.01.016

Cite this

Iruzubieta, P., Bataller, R., Arias-Loste, M. T., Arrese, M., Calleja, J. L., Castro-Narro, G., Cusi, K., Dillon, J. F., Martínez-Chantar, M. L., Mateo, M., Pérez, A., Rinella, M. E., Romero-Gómez, M., Schattenberg, J. M., Zelber-Sagi, S., Crespo, J., & Lazarus, J. V. (2023). Research Priorities for Precision Medicine in NAFLD. Clinics in Liver Disease, 27(2), 535-551. https://doi.org/10.1016/j.cld.2023.01.016

@article{524dec73cc2c44329f74d97e49c47f45,

title = "Research Priorities for Precision Medicine in NAFLD",

abstract = "NAFLD is a multisystem condition and the leading cause of chronic liver disease globally. There are no approved NAFLD-specific dugs. To advance in the prevention and treatment of NAFLD, there is a clear need to better understand the pathophysiology and genetic and environmental risk factors, identify subphenotypes, and develop personalized and precision medicine. In this review, we discuss the main NAFLD research priorities, with a particular focus on socioeconomic factors, interindividual variations, limitations of current NAFLD clinical trials, multidisciplinary models of care, and novel approaches in the management of patients with NAFLD.",

keywords = "Disease phenotyping, Multidisciplinary care, NAFLD, Non-invasvie tests (NITs), Precision medicine",

author = "Paula Iruzubieta and Ramon Bataller and Arias-Loste, \{Mar{\'i}a Teresa\} and Marco Arrese and Calleja, \{Jos{\'e} Luis\} and Graciela Castro-Narro and Kenneth Cusi and Dillon, \{John F.\} and Mart{\'i}nez-Chantar, \{Mar{\'i}a Luz\} and Miguel Mateo and Antonio P{\'e}rez and Rinella, \{Mary E.\} and Manuel Romero-G{\'o}mez and Schattenberg, \{J{\"o}rn M.\} and Shira Zelber-Sagi and Javier Crespo and Lazarus, \{Jeffrey V.\}",

note = "Funding Information: J.L. Calleja reports consultancy and speaker fees from Echosens, Advanz Ph, and MSD, outside of the submitted work. K. Cusi is a consultant for Altimmune, Akero, Arrowhead, AstraZeneca, 89Bio, BMS, Coherus, Intercept, Lilly, Madrigal, Merck, Novo Nordisk, Quest, Sagimet, Sonic Incytes, Terns, Thera Technologies, and MSD, outside of the submitted work. J.F. Dillon has received research grants and lecture honoraria from MSD , AbbVie, and Gilead , outside of the submitted work. M.L. Mart{\'i}nez-Chantar advises for Mitotherapeutix LCC, outside of the submitted work. J.M. Schattenberg reports consultancy for Apollo Endosurgery, Albireo Pharma Inc, Bayer, BMS, Boehringer Ingelheim, Echosens, Gilead Sciences, GSK, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Madrigal, MSD, Nordic Bioscience, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and Siemens Healthcare GmbH and research Funding from Gilead Sciences , Boehringer Ingelheim , Nordic Bioscience , and Siemens Healthcare GmbH , outside of the submitted work. J. Crespo reports consulting and personal fees from Gilead Sciences, AbbVie, MSD, Shionogi, Intercept Pharmaceuticals, Janssen Pharmaceuticals Inc, Celgene, and Alexion, outside of the submitted work. J.V. Lazarus acknowledges grants and speaker fees from AbbVie, Gilead Sciences, and MSD and speaker fees from Genfit, Intercept, Janssen, Novo Nordisk, and ViiV, outside of the submitted work. P. Iruzubieta, R. Bataller, M.T. Arias-Loste, M. Arrese, G. Castro-Narro, M. Mateo, A. P{\'e}rez, M.E. Rinella, M. Romero-G{\'o}mez, and S. Zelber-Sagi have nothing to disclose. Funding Information: The authors acknowledge the Valdecilla Biomedical Research Institute (Santander, Spain) for supporting the International Precision Medicine Forum: NAFLD Updated. J.V. Lazarus acknowledges institutional support to ISGlobal from the Spanish Ministry of Science , Innovation and Universities, through the “Centro de Excelencia Severo Ochoa 2019 to 2023” Program ( CEX2018-000806-S ), and from the Government of Catalonia , Spain, through the CERCA Programme. Funding from the Spanish Instituto de Salud Carlos III Grant (FIS - PI18/01304 to J. Crespo) and from the Agencia Nacional de Investigaci{\'o}n y Desarrollo ( ANID) , Chile (to M. Arrese) is also acknowledged.",

year = "2023",

month = may,

doi = "10.1016/j.cld.2023.01.016",

language = "American English",

volume = "27",

pages = "535--551",

journal = "Clinics in Liver Disease",

issn = "1089-3261",

publisher = "W.B. Saunders",

number = "2",

}

Iruzubieta, P, Bataller, R, Arias-Loste, MT, Arrese, M, Calleja, JL, Castro-Narro, G, Cusi, K, Dillon, JF, Martínez-Chantar, ML, Mateo, M, Pérez, A, Rinella, ME, Romero-Gómez, M, Schattenberg, JM, Zelber-Sagi, S, Crespo, J & Lazarus, JV 2023, 'Research Priorities for Precision Medicine in NAFLD', Clinics in Liver Disease, vol. 27, no. 2, pp. 535-551. https://doi.org/10.1016/j.cld.2023.01.016

TY - JOUR

T1 - Research Priorities for Precision Medicine in NAFLD

AU - Iruzubieta, Paula

AU - Bataller, Ramon

AU - Arias-Loste, María Teresa

AU - Arrese, Marco

AU - Calleja, José Luis

AU - Castro-Narro, Graciela

AU - Cusi, Kenneth

AU - Dillon, John F.

AU - Martínez-Chantar, María Luz

AU - Mateo, Miguel

AU - Pérez, Antonio

AU - Rinella, Mary E.

AU - Romero-Gómez, Manuel

AU - Schattenberg, Jörn M.

AU - Zelber-Sagi, Shira

AU - Crespo, Javier

AU - Lazarus, Jeffrey V.

N1 - Funding Information: J.L. Calleja reports consultancy and speaker fees from Echosens, Advanz Ph, and MSD, outside of the submitted work. K. Cusi is a consultant for Altimmune, Akero, Arrowhead, AstraZeneca, 89Bio, BMS, Coherus, Intercept, Lilly, Madrigal, Merck, Novo Nordisk, Quest, Sagimet, Sonic Incytes, Terns, Thera Technologies, and MSD, outside of the submitted work. J.F. Dillon has received research grants and lecture honoraria from MSD , AbbVie, and Gilead , outside of the submitted work. M.L. Martínez-Chantar advises for Mitotherapeutix LCC, outside of the submitted work. J.M. Schattenberg reports consultancy for Apollo Endosurgery, Albireo Pharma Inc, Bayer, BMS, Boehringer Ingelheim, Echosens, Gilead Sciences, GSK, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Madrigal, MSD, Nordic Bioscience, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and Siemens Healthcare GmbH and research Funding from Gilead Sciences , Boehringer Ingelheim , Nordic Bioscience , and Siemens Healthcare GmbH , outside of the submitted work. J. Crespo reports consulting and personal fees from Gilead Sciences, AbbVie, MSD, Shionogi, Intercept Pharmaceuticals, Janssen Pharmaceuticals Inc, Celgene, and Alexion, outside of the submitted work. J.V. Lazarus acknowledges grants and speaker fees from AbbVie, Gilead Sciences, and MSD and speaker fees from Genfit, Intercept, Janssen, Novo Nordisk, and ViiV, outside of the submitted work. P. Iruzubieta, R. Bataller, M.T. Arias-Loste, M. Arrese, G. Castro-Narro, M. Mateo, A. Pérez, M.E. Rinella, M. Romero-Gómez, and S. Zelber-Sagi have nothing to disclose. Funding Information: The authors acknowledge the Valdecilla Biomedical Research Institute (Santander, Spain) for supporting the International Precision Medicine Forum: NAFLD Updated. J.V. Lazarus acknowledges institutional support to ISGlobal from the Spanish Ministry of Science , Innovation and Universities, through the “Centro de Excelencia Severo Ochoa 2019 to 2023” Program ( CEX2018-000806-S ), and from the Government of Catalonia , Spain, through the CERCA Programme. Funding from the Spanish Instituto de Salud Carlos III Grant (FIS - PI18/01304 to J. Crespo) and from the Agencia Nacional de Investigación y Desarrollo ( ANID) , Chile (to M. Arrese) is also acknowledged.

PY - 2023/5

Y1 - 2023/5

N2 - NAFLD is a multisystem condition and the leading cause of chronic liver disease globally. There are no approved NAFLD-specific dugs. To advance in the prevention and treatment of NAFLD, there is a clear need to better understand the pathophysiology and genetic and environmental risk factors, identify subphenotypes, and develop personalized and precision medicine. In this review, we discuss the main NAFLD research priorities, with a particular focus on socioeconomic factors, interindividual variations, limitations of current NAFLD clinical trials, multidisciplinary models of care, and novel approaches in the management of patients with NAFLD.

AB - NAFLD is a multisystem condition and the leading cause of chronic liver disease globally. There are no approved NAFLD-specific dugs. To advance in the prevention and treatment of NAFLD, there is a clear need to better understand the pathophysiology and genetic and environmental risk factors, identify subphenotypes, and develop personalized and precision medicine. In this review, we discuss the main NAFLD research priorities, with a particular focus on socioeconomic factors, interindividual variations, limitations of current NAFLD clinical trials, multidisciplinary models of care, and novel approaches in the management of patients with NAFLD.

KW - Disease phenotyping

KW - Multidisciplinary care

KW - NAFLD

KW - Non-invasvie tests (NITs)

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85150393899&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2023.01.016

DO - 10.1016/j.cld.2023.01.016

M3 - Review article

C2 - 37024222

SN - 1089-3261

VL - 27

SP - 535

EP - 551

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

IS - 2

ER -

Research Priorities for Precision Medicine in NAFLD

Abstract

UN SDGs

Keywords

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this